Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests a new drug called SKB565 in 180 adults (ages 18-75) with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right …

This study tests a drug called Sac-TMT in 30 people with advanced thymic carcinoma that has worsened after platinum chemotherapy. Participants receive the drug every two weeks, and doctors check tumor response every six weeks. The goal is to see if the drug shrinks tumors and to …

This study tests a new drug combination (SKB571) in 150 adults with non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and how safe it is. Participants must have measurable tumors and be in good overall health.

This study tests a new drug, SKB118, in about 332 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The trial has three parts to find the best dose and see if the drug shrinks tumors. The main goals are safet…

This study tests a new drug called SKB571 in 120 adults with gastrointestinal tumors. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for side effects and cancer progression. The study is not yet recruiting.

This study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…